Artificial intelligence and care delivery company Akido Labs Inc. announced today that it has raised $60 million in new funding to expand the reach of ScopeAI, a system aimed at increasing clinical capacity and improving healthcare access.

Founded in 2015, Akido is a health technology company focused on using AI to expand access to high-quality care, particularly for vulnerable and underserved populations. The company combines AI-powered software with a network of multispecialty clinics to deliver efficient, whole-person care at large scale.

At the core of Akido’s offering is ScopeAI, an AI-driven clinical co-pilot that assists medical assistants and physicians during patient visits. ScopeAI dynamically generates relevant clinical questions, captures patient responses in real time and drafts documentation, including notes, diagnoses and care plans, to reduce the administrative burden on healthcare providers.

ScopeAI is designed to operate as a reinforcement-learning system, a model that learns and improves over time by receiving feedback from its actions and adjusting its behavior to maximize desired outcomes. The ongoing training loop helps refine the model’s accuracy over time, ensuring it adapts to clinical nuance while supporting faster, safer decision-making across diverse patient populations.

The idea is that by automating large portions of the intake and documentation process, ScopeAI allows providers to see more patients without compromising on quality. Users can also expand care access, even in high-demand settings such as street medicine programs and public clinics.

“We built ScopeAI to tackle the single biggest challenge facing healthcare systems worldwide: the physician shortage,” explains co-founder and Chief Executive Prashant Samant. “With demand for care far exceeding supply, AI is the key to addressing the global doctor deficit, empowering healthcare providers and ensuring patients receive the timely, high-quality care they deserve, regardless of financial means or geography.”

The Series B round was led by Oak HC/FT Partners LP. Greco Risk Partners, SNR Denton Group Ltd. and existing investors Y Combinator, Future Communities Capital, Jeff Dean, chief scientist at Google DeepMind and Google Research, and the Comprehensive Blood & Cancer Center Inc. also participated.

“Akido is delivering on the promise of changing how patients experience a visit with their provider through AI,” said Andrew Adams, co-founder and managing partner at Oak HC/FT. “With its robust, longitudinal dataset, Akido has the refinement in its foundational model to offer clinical accuracy where others have struggled.”

Image: Akido Labs